Effectiveness of available phosphate binders: A comparitative review

Sonali Singh, Rohit Kumar, Parminder Nain


Chronic kidney disease (CKD) is the leading cause of deathworldwide.
Hyperphosphatemia is the most common clinical manifestation observed in
CKD. Various drugs are available for the treatment of Hyperphosphatemia in
CKD. But most of them shows severe adverse effects thus cannot be used for
long term treatment. A number of trials are set in order to find the most
appropriate phosphate binders. The result shows Sevalamer as the most
favourable drug for Hyperphospatemia

Full Text:



  • There are currently no refbacks.